^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
New
Source:
Title:

Preliminary Clinical Response Data from a Phase 1b Study of Mavorixafor in Combination with Ibrutinib in Patients with Waldenström’s Macroglobulinemia with MYD88 and CXCR4 Mutations

Published date:
11/04/2021
Excerpt:
This is an ongoing phase 1b, open-label, multicenter, single-arm study (NCT04274738) examining mavorixafor in combination with ibrutinib...Four of 8 patients achieved major response; 1 of 8 patients achieved very good partial response....These ongoing studies support the feasibility of combining ibrutinib with mavorixafor to improve responses in MYD88 CXCR4WHIM WM.
DOI:
10.1182/blood-2021-144706
Trial ID: